- Company
- Hyundai Introduces Estrogen-Free Contraceptives
- by Jun 23, 2022 05:50am
- Hyundai Pharmaceutical (CEO Lee Sang-joon) announced on the 21st that it has signed an exclusive license agreement with Asuka Pharmaceutical in Korea for the oral contraceptive Slinda"with Drospirenone only. Slinda is a product developed by Exeltis, a women's medical brand division in Insud Pharma, Spain. Unlike the existing fourth-genera
- Company
- The third challenge of Imbruvica's primary therapy
- by Eo, Yun-Ho Jun 22, 2022 05:59am
- BTK inhibitor Imbruvica will take on its third challenge to expand insurance benefits. According to related industries, the first-line therapy indication of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in Imbruvica will be presented again to the HIRA Cancer Disease Review Committee on the 29th. Imbruvica's first-l
- Company
- K-botulinum products are expanding globally
- by Jun 22, 2022 05:59am
- Domestic botulinum toxin is entering various parts of the world. Feeling limited in the domestic market, developers are targeting the U.S., Europe, and China, which are the largest markets in the world, while expanding their scope to countries such as Australia and the Middle East. ◆ Hugel is targeting Europe and North America, and Chi
- Company
- Takeda Korea appoints Sun Jin Lee as head of Oncology BU
- by Jun 21, 2022 05:54am
- Takeda Pharmaceuticals Korea (General Manager HeeSeok Moon) announced on the 20th that it had promoted and appointed Manager Sun Jin (Justine) Lee as the Head of its Oncology BU. The new head, Lee, who joined Takeda Pharmaceuticals Korea as a marketing manager of the Hemophilia BU, developed creative marketing strategies and drew particip
- Company
- KIMS has signed a license agreement for Lipothasone
- by Nho, Byung Chul Jun 21, 2022 05:54am
- KIMS Pharmaceutical announced on the 20th that it has signed a contract with Japanese pharmaceutical company Mitsubishi Tanabe Pharma on the 17th to license Lipothasone. Through this contract, KIMS Pharmaceutical will officially release the product in August. According to KIMS Pharmaceutical, Lipothasone is the only Dexamethasone in Korea
- Company
- 11 of the national essential drugs are non reimbursed
- by Eo, Yun-Ho Jun 20, 2022 06:04am
- It was found that 11 of the drugs designated by The National Essential Medicine, excluding vaccines, are still non-reimbursed. As of December 31, 2021, 511 species have been designated as the National Essential Medicine, and 158 types of infectious disease-related drugs excluding vaccines. Of these, 11 drugs were not on the insurance benef
- Company
- TNBC will be added to Keytruda's indications
- by Eo, Yun-Ho Jun 20, 2022 06:04am
- TNBC indications of the immuno-cancer drug Keytruda are expected to be added. According to related industries, the MFDS is currently conducting a last-minute review for further approval of the combination of chemotherapy in the first round of Triple-Negative Breast Cancer (TNBC) by PD-1 inhibitor Keytruda. Permission is expected within the th
- Company
- Hee-Mok Won to “strengthen ties with Korean talents in US"
- by Kim, Jin-Gu Jun 20, 2022 06:03am
- The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) announced on the 16th that it will establish a communication and cooperation network with Korean talents that serve key roles in regulatory agencies, pharmaceutical companies, and venture capital (VCs) in the US to support the domestic companies’ entrance into the US
- Company
- Myungin challenges generic for exclusivity of Brintellix
- by Jun 20, 2022 06:03am
- Domestic pharmaceutical companies have launched an antidepressant Brintellix first generic challenge. According to the pharmaceutical industry on the 16th, Myungin and Unimed filed an application with the MFDS this month to approve generics of Lundbeck Korea Brintellix. It has been five months since the two companies filed a trial to confi
- Company
- The α-GPC's sentence of lawsuit has been postponed again
- by Chon, Seung-Hyun Jun 20, 2022 06:03am
- The sentence of the "cancellation of benefit reduction" lawsuit of the brain function improvement drug Choline Alfoscerate has been postponed again. According to the industry on the 16th, the 6th part of the Seoul Administrative Court changed the date of the lawsuit for cancellation of the notification of the application of health insuranc
